Health Velocity Capital

RA Capital Management is a multi-stage investment manager dedicated to company formation and evidence-based investing in healthcare and life science companies developing drugs, medical devices, diagnostics, services, and research tools. The firm’s portfolio of private and public companies spans the globe and most therapeutic areas across all stages from discovery through commercialization. We are committed to fostering diversity at RA, in our portfolio companies, and in the broader biotech community. Who We AreOur flexible strategy allows us to provide seed funding to startups and lead private, IPO, and follow-on financings for our portfolio companies, thereby driving value creation from idea inception through commercialization. At RA Capital’s core is its TechAtlas research division, a scientifically trained team that maps out competitive landscapes to put data into context, identify breakthroughs, and originate conviction in new ideas. TechAtlas provides market intelligence and, technical diligence, and other resources to both our internal Investment Team and our portfolio companies. The team’s understanding of industry best practices is derived from an extensive collection of case studies documenting the impact of clinical trial design, partnership structures, and public market dynamics. Beyond CapitalRA Capital offers its portfolio companies much more than capital to help them grow, make decisions, and succeed. We:Serve on boards of private and public companies and host board meetings at our offices Help recruit executives and board members Provide access to TechAtlas maps and expertise Prioritize indications and targets based on their feasibility and value given current scientific knowledge, unmet needs, and emerging competition Monitor for new applications and complementary technologies Create custom maps that lay out a company’s competition and unrealized opportunities Provide extra analytical bandwidth across our large team (e.g., analyze literature, provide insights from scientific and investor conferences) Assist with grant writing and preparation of scientific publications Interview clinicians and key opinion leaders (KOLs) Host advisory boards Facilitate partnership or acquisition discussions with larger companies Help design (or redesign) a corporate slide deck or website, leveraging in-house writing and graphics teams Make introductions to other investors Anchor subsequent financings and set the pace for closing Help select bankers for financings and M&A We also provide a growing suite of Innovator Resources to the broader ecosystem, with more hands-on support for our portfolio companies, management teams, and boards. These resources include: a comprehensive reference guide to conducting successful biotech board meetings; a data-driven guide to how to conduct a logical IPO based on first principles of price discovery and shareholder alignment; and a roadmap for how to convey your company’s unique Equity Value Proposition to employees (because they are also your investors). We’re available to coach you through a pitch, provide feedback on a deck, and partner with you to refine strategy or messaging at every stage. Additionally, we helped to found and continue to support No Patient Left Behind, a non-profit dedicated to promoting affordability of today’s medicines and the development of better ones. More specifically, NPLB advocates for insurance reforms that would allow all patients to afford the treatments they need, draws attention to the full societal value of all medicines and the merits of ensuring that all drugs go generic without delay, and educates lawmakers and the public about the workings of the biomedical ecosystem to protect it against misguided policies. Translation & HuntingRA Capital offers Executive-In-Residence (EIR) and venture partner programs for experienced professionals seeking thought partners. We welcome experienced drug hunters searching for technologies/candidates and looking to start new companies to collaborate with our team, explore the capabilities of our in-house incubator, and take advantage of the breadth and depth of our TechAtlas platform. RAVen, our in-house incubator, provides a collaborative platform for drug hunters and company builders to explore both the novel and the re-imagined. Discoveries and improvements in chemistry, molecular and cellular biology, and materials science create novel capabilities that may address unsolved challenges. Our understanding of fundamental biology is constantly evolving, revealing new applications for existing technologies and partially-developed drug candidates. Programs we consider worthwhile may form the basis for a new venture. We believe that when a business proposition is framed correctly, the capital markets have adequate resources and understanding to fund proper experimental design and solution development without forcing companies to cut corners. Furthermore, we have collaborated extensively with other funds that share our philosophy to enable ambitious and capital-intensive endeavors. Our ValuesWe at RA Capital are introspective and deliberate about the ways in which we engage with each other and those outside our firm. Our values represent a set of clear parameters by which we create working relationships founded on trust, collaboration, diligence, and integrity.We originate conviction. We do not borrow it from others. We expect and strive to inspire the best in everyone. We embrace the unfamiliar. We do not let convention stand in the way of what is right. We learn collaboratively. We have a bias for action. We are persistently curious and humbled by what is left to learn. We are data-driven and challenge assumptions. We preserve the ability to change our mind. We admit our mistakes and share lessons learned. We address the elephant in the room. We value our relationships and are positive, respectful, and open-minded. We take fun seriously.

We believe that the future of modern healthcare is led by a digital revolution. Investing in solutions that help to transforms these challenges healthcare is facing. When technology is fuelled by digitalisation, innovation will thrive and grow, creating leverage for global reform. By supporting innovative digital-health startups with seed capital, extensive industry knowledge and a powerful global network, we aim to change the future of healthcare forever. Entrepreneurial capital: Our work is rooted in a deep understanding of the system in which we operate. Pioneering: We believe that the future of modern healthcare is led by a digital revolution. Committed to impact: There is an idealistic element to our proposition. The aim of our efforts is change. Human centred: People are at the core of everything we do. They are the end to our means and the why to our what. From a business perspective this translates into a strong desire to invest in a team, rather than a business plan. We believe in long term shared success. The Approach In return for the invested capital and support, Healthy.Capital acquires a minority share. We are: Team with experts Entrepreneurs by heart Specialist in building product-market fit Long term investment relationships Digital Health VC with international network Ecosystem key player Our initially invested capital ranges between EUR 200K and EUR 1 M. Once a board, and depending on the proposition, we will offer support with a startup mentality in the following areas: Strategy Building Coaching Operational Expertise Business Development Health & Care Expertise Co-investments Financial Roadmap Planning Network Expansion Healthy.Capital invests in talented founders & teams. Our focus is Digital Health Solutions Services SaaS Marketplaces Our Criteria Business entity registered in the Netherlands Company younger than 7 years old Tech component (pre-)Seed stage Excellent teams Data driven DNA Strong problem-solution fit High scalability with healthy profitability

At Flare Capital, we do more than simply provide capital for early stage and emerging healthcare technology companies. We partner with the most creative and passionate entrepreneurs aspiring to reinvent the business of healthcare. Together we work to build transformational companies that will profoundly improve the delivery and quality of healthcare while reducing costs. Our Team In 2014, Michael and Bill came together with the vision to build the leading dedicated healthcare technology venture capital firm. Both had started successful venture firms earlier in their careers and had a shared perspective on what the market now needed. As the “business of healthcare” is being transformed, there are significant opportunities to create important and enduring new healthcare technology companies. Given the complexity of this sector, a focused investment strategy with an experienced, committed team is required, and thus Flare Capital was launched. The firm is comprised of a number of proven healthcare technology investors with both deep industry knowledge and venture capital experience alongside accomplished operating executives of leading healthcare organizations. Our Executive Partners have substantial operating experience and our Industry Advisory Board includes many of the brightest healthcare minds with unique perspectives from across the industry. Together they provide critical insights and points of connectivity for our team at Flare Capital and are a tremendous resource for our entrepreneurs. Our Flare Scholars are professionals from preeminent healthcare companies and students from academic institutions across the country who scout interesting people and investment opportunities for us while learning about venture capital. Our Investors We have hand-assembled some of the most successful healthcare organizations, leading family offices, pension funds and investment companies as investors. At Flare Capital, we are privileged to partner with and have unparalleled access to leading innovative healthcare providers, payers, medical device companies, laboratory services provider, healthcare retailer, and one of the largest owners of healthcare campuses. Our investors have an enormous footprint in healthcare and are on the forefront of healthcare innovation. Our Approach We invest across the United States, recognizing that healthcare technology innovation is occurring in many cities around the country. While we consider ourselves principally early stage investors, we are full lifecycle investors. We partner with our entrepreneurs across the entire journey of company building. We are committed to our entrepreneurs and to being their first call, as we work closely and patiently through all strategic issues confronting our companies, maximizing their probability of success. In particular, we are very focused on assisting with recruiting and securing early customer validation and revenues. Starting and then scaling a successful healthcare technology company is hard. Careful and thoughtful financing strategies need to map to detailed product development timelines and other commercial milestones. We closely collaborate with our entrepreneurs to ensure that they have critical access to the best resources as the business scales. We relentlessly strive to be a true partner and to deliver extraordinary value to our entrepreneurs to enable them to build market leading, transformational businesses.

We have nearly 300 companies in our portfolio including over 30 that we started from scratch. Our global portfolio is spread across the Americas, Europe, and Asia. Over four and a half billion dollars under management. Big ideas need big investments. We have the heft and history to make a significant impact in the world. Healthcare: We create and invest in leading companies in therapeutics, medtech, and health IT & services. Technology: We've been partnering with fearless founders for over 50 years.

Established in 2022, Valspring is a Boston-based growth equity firm founded by the former healthcare investment team of Bain Capital Ventures. With deep sector expertise and a proven track record, we invest in growth-stage companies in the healthcare industry, focusing on the information technology, technology-enabled services and services sectors.

Founded over 20 years ago, Kaiser Permanente Ventures has developed into a national leader in strategic venture investing in healthcare. In partnership with Kaiser Permanente and our limited partners, the KPV team has invested in and helped support over 65 companies, representing some of the most important innovations in healthcare delivery over this time period. We’ve achieved these successes through deep engagement within KP and across our investment partners, leveraging the tremendous insights that come from those leading our healthcare systems and care delivery to identify the most pressing needs within healthcare and select the innovations that most effectively address those opportunities. Together with our partners, KP and KPV represents22,000+ clinicians and over 180,000 healthcare employees 38+ acute care hospitals and over 600 other healthcare-related facilities Approximately $65 billion in annual operating revenue Largest U.S. single comprehensive electronic medical record system Leading evidence-based care delivery mode Our fund targetsHealth Information Technology (Enterprise Solutions) Digital Health Healthcare Services Medical Devices Diagnostics and Precision Medicine